知镜 Cognispect · 医学文献与研究工作台

Certolizumab Pegol


· 2026-07-15 · PMID 30000714

文献摘要

Certolizumab is excreted into breastmilk in some, but not all, women in small amounts. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Polyethylene glycol is not excreted into breastmilk.[2] Numerous experts and professional guidelines have stated that the drug is a low risk to the nursing infant and acceptable to use during breastfeeding.[3-11] Anti-TNF agents appear to reduce the levels of tumor necrosis factor and IP-10 in the milk of mothers with inflammatory bowel disease in the early postpartum period.[12] This reduction in TNF might lead to decreased milk production, so extra lactation support might be necessary in women taking certolizumab pegol.

在知镜精读原文来源

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。